References
- Dulitzki M, Pauzner R, Langevitz P, Pras M, Many A, Schiff E. Low molecular weight heparin during pregnancy and delivery: Preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87: 380–3.
- Fejgin MD, Lourwood DL. Low molecular weight heparins and their use in obstetrics and gynecology. Obstet Gynecol Surv 1994; 49: 424–31.
- Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemnerton KD et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652–6.
- Greer IA, de Swiet M. Thrombosis prophylaxis in obstetrics and gynecology. Br J Obstet Gynecol 1993; 100: 37–40.
- Nelson-Piercy C. Low molecular weight heparin for obstetric thrombo prophylaxis. Br J Obstet Gynecol 1994; 101: 6–8.
- Nelson-Piercy C, Letsky EA, de Sweit M. Low molecular weight heparin for obstetric thrombo prophylaxis: Experience of sixty nine pregnancies in sixty one women at high risk. Obstet Gynecol 1997; 176: 1062–1068
- Matzch T, Bergqvist D, Hodson S, Dawes J, Hender U, Ostergaard P. No placental passage of heparin or an enzymatically depolymerized low molecular weight heparin. Blood Coagul Fibrinolysis 1991; 2: 273–8.
- Omri A, Delaloye JF, Anderson H, Bachmann F. LMW heparin novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989; 61: 55–6.
- Sanson BJ, Lensing AWA, Prins MH, Ginsberg JS, Barkagan ZS, Lavenne-Pardonge E et al. Low molecular weight heparin in pregnancy: a systematic review. Thromb Hamost 1999; 81: 668–72.
- Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in preg-nancy. Br J Obstet Gynecol 2000; 107: 1116–21.
- Hynson JM, Katz JA, Bueff HU. Epidural hematoma associated with enoxaprin. Anesth Analg 1996; 82: 1072–5.
- Bergqvist D, Lindblad B, Matzch T. Risk of combining low molecular weight heparin for thrombophilaxis and epidural or spinal anesthesia. Semin Thromb Hemost 1993; 19 (suppl 1): 147–51.
- Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; (supp 119): 122–31.
- Kandrotas RJ. Heparin pharmacokinetics and pharmaco-dynamics. Chin Pharmcokinet 1999; 22: 359–74.
- Blomback M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of daleparin during late pregnancy. Blood Coagul Fibrinolysis 1998; 9: 343–50.
- Casele HL, Laifer SA, Woelkers DA, et al. Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999; 181: 1113–7.
- Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688–98.
- Horlocker TT, Heit JA. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regi-mens, and guidelines for regional anesthetic management. Anesth Analg 1997; 85: 874–85.
- Chan WS, Ray JG. Low molecular weight heparin use during pregnancy: Issues of safety and practicality. Obstet Gynecol Surv 1999; 54: 649–54.
- Greer, IA. Thrombosis in pregnancy: Maternal and fetal issues. Lancet 1999; 353: 1258–65.
- Greer IA. The acute management of venous thromboembo-lism in pregnancy. Curr Opin Obstet Genecol 2001,13; 569–75.
- Horlocker TT. Low molecular weight heparin and neuraxial anesthesia. Thromb Res 2001; 101: 141–54.
- Waegerle JD. Regional anesthesia and issues of coagulation status. CRNA 2000; 11: 66–71.
- Yin B, Barratt SM, Power I, Perey J. Epidural haematoma after removal of an epidural catheter in a patient receiving high dose enoxaparin. Br Anaesth 1999; 82: 288–90.
- Wysowski DK, Lim J. Spinal and epidural hematoma and low molecular weight heparin. N Engl J Med 1998; 338: 1774–5.